(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
"For the blood is the life . . . . "(Deut. 12 :23) " . . . because the blood, in its value as life, makes atonement" (Lev. 17: 11) HemoPhilia is a rare disease, severe hemophilia rarer still, yet the written history of hemophilia extends back over a millennium and a half. In the ancient Middle East, blood and life were coupled. Blood was the primary substance necessary for life, given to God in sacrifice and forbidden as a food to mortals by Levitical law. Blood was essential for rites of purification and consecration. But the flow of blood during menstruation or parturition rendered a woman unclean. The circumcision of a male child required 33 days of "blood purification" by the mother. ' Circumcision, the visible reminder of the covenant of Abraham lijith Yahweh, was required of newborn Jewish males. It "connote(d) suitability for participation in what God is doing. "2 Hence, free and uncontrolled bleeding of the male child during circumcision, during the ratification of God's covenant, would be noted with awe and concern by those of the Jewish faith. It should not be surprising that the first genetic counseling offered to families with hemophilia is found in the Babylonian Talmud (compilation of Jewish law dated to about the third century AD) and concerns the necessity for circumcision in families with what we would now call hemophilia.
Contents:
Factors VIII, IX and von Willebrand Factor: Their Molecular and Antigenic Structure: An Overview: Molecular Etiology of Factor VIII Deficiency in Hemophilia A; S.E. Antonarakis, et al. Epitope Specificity and Functional Charaterization of Factor VIII Inhibitors D. Scandella; et al. The Molecular Basis of the Human Immune Response: Bcell Epitopes: Fact and Fiction;D.C. Benjamin Antigen Analogs as Therapeutic Agents; J. Alexander, et al. Genetic Variation and the Immune Response: Tcell Receptors in Immune Responses; M.A. Robinson Immunoglobin Heavy Chain Variable Gene Usage in Human Autoimmune Diseases; V. Pascual, J.D. Capra Treatment of Inhibitors: Porcine Factor VIII Therapy in Patients with Factor VIII Inhibitors; C. Hay, J.N. Lozier Clinical Presentation and Management of Patients with Circulating Anticoagulants; A. Moliterno, W.R. Bell Tolerance to Coagulation Factors: Multiple Mechanisms of Immunologic Tolerance: Novel Approaches for Unresponsiveness; D.W. Scott New Approaches to the Inhibitor Problem: Variable(V) Regionmediated Control of Autoreactivity to Factor VIII; M.D. Kazatchkine; et al. Panel Discussion on the Development of Inhibitors: Who and Why? Panel Discussion on the Treatment of Inhibitors: Today and Tomorrow. 12 additional articles. Index.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: October, 2011
Pages: 324
Weight: 568g
Availability: Available
Subcategories: Genetics, Immunology, Pharmacology
From the same series
